Background/Aims: Primary pigmented nodular adrenocortical disease (PPNAD) is associated with inactivating germline protein kinase A regulatory subunit type 1-α (PRKAR1A) mutations and loss of heterozygosity at the 17q22–24 locus in approximately 50% patients. PRKAR1A mutations are observed in both isolated PPNAD (iPPNAD) and Carney complex (CNC). Most mutations result in a functionally null-allele and exhibit high penetrance. We genotyped members of an extended family for a novel PRKAR1A mutation and undertook detailed phenotyping for CNC in the affected individuals. Methods: A 10.5-year-old male was diagnosed with PPNAD; the patient’s mother also had iPPNAD. A 13-year-old sibling and 7 other relatives (mean age 58.2, range 29.1–80.2 years) were referred for PRKAR1A mutation analysis. Results: DNA analysis of the index case and parent revealed a novel germline heterozygous PRKAR1A mutation at the +1 position of the acceptor site of intron 3 [c.349 G>T]. The same heterozygous splice site mutation was present in the sibling with no PPNAD or CNC manifestations and 2 other individuals aged 54.9 and 57.1 years who had subclinical Cushing’s syndrome but no features of CNC. Conclusion: We conclude that c.349 G>T, a novel splice site germline PRKAR1A defect, has low penetrance resulting in incomplete clinical expression in this kindred.

1.
Stratakis CA, Kirschner L, Carney J: Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;4041–4046.
2.
Stratakis CA, Sarlis N, Kirschner L, Carney J, Doppman J, Nieman L, Chrousos G, Papaniconlaou D: Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 1999;585–591.
3.
Sandrini F, Stratakis C: Clinical and molecular genetics of Carney complex. Molec Genet Metab 2003;83–92.
4.
Sarlis NJ, Chrousos G, Doppman J, Carney J, Stratakis C: Primary pigmented nodular adrenocortical disease: reevaluation of a patient with Carney complex 27 years after unilateral adrenalectomy. J Clin Endocrinol Metab 1997;1274–1278.
5.
Carney JA, Young W: Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist 1992;6–21.
6.
Carney JA, Gordon H, Carpenter P, Shenoy B, Gomez M: The complex of myxomas, spotty pigmentation and endocrine overactivity. Medicine (Baltimore) 1985;270–283.
7.
Stratakis CA, Kirschner L: Clinical and genetic analysis of primary bilateral adrenal diseases (micro- and macronodular disease) leading to Cushing’s syndrome. Horm Metab Res 1998;456–463.
8.
Sandrini F, Stratakis C: Clinical and molecular genetics of Carney complex. Molec Genet Metab 2003;83–92.
9.
Stergiopoulos SG, Stratakis C: Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease! FEBS Lett 2003;59–64.
10.
Cazabat L, Ragazzon B, Groussin L, Bertherat J: PRKAR1A mutations in primary pigmented nodular adrenocortical disease. Pituitary 2006;211–219.
11.
Boikos SA, Stratakis C: Carney complex: the first 20 years. Curr Opin Oncol 2007;24–29.
12.
Groussin L, Kirschner L, Vincent-Dejean C, Perlemoine K, Louvel A, Leheup B, Luton JP, Bertagna X: Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 2002;1433–1442.
13.
Kirschner LS, Sandrini F, Monbo J, Lin J, Carney J, Stratakis C: Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Molec Genet 2000;3037–3046.
14.
Kirschner LS, Stratakis C: Genetic analysis of Carney complex: current understanding and future questions. Curr Opin Endocrinol Diabetes 2002;244–249.
15.
Kirschner LS, Carney J, Pack S, Taymans S, Giatzakis C, Cho Y, Cho-Chung Y, Stratakis C: Mutations of the gene encoding the protein kinase A type 1-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;89–92.
16.
Greene EL, Horvath A, Nesterova M, Giatzakis C, Bossis I, Stratakis C: In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay. Hum Mutat 2008;633–639.
17.
Meador CK, Bowdoin B, Owen W, Farmer T: Primary adrenonodular dysplasia: a rare cause of Cushing’s syndrome. J Clin Endocrinol Metab 1967;1255–1263.
18.
Groussin L, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton J-P, Bertagna X, Bertherat J: Mutations of the PRKAR1A gene in Cushing’s syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab 2002;4324–4329.
19.
Groussin L, Horvath A, Jullian E, Boikos S, Rene-Corail F, Lefebvre H, Cephise-Velayoudom F, Vantyghem M, Chanson P, Conte-Devolx B, Lucas M, Gentil A, Malchoff C, Tissier F, Carney J, Bertagna X, Stratakis C, Bertherat J: A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. J Clin Endocrinol Metab 2006;1943–1999.
20.
Storr, HL, Mitchell H, Swords F, Main K, Hindmarsh P, Betts P, Shaw N, Johnson D, Clark A, Reznek R, Grossman A, Savage M: Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing’s syndrome due to primary nodular adrenocortical hyperplasia. Clin Endocrinol 2004;553–559.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.